^
Association details:
| Biomarker: | PIK3CA mutation + HR negative |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Application of capture-based sequencing in predicting pathologic response to neoadjuvant therapy in HER2-positive breast cancer.
Published date:
05/16/2018
Excerpt:
...31 hormonal receptor (HR)-negative HER2-positive BC patients treated with neoadjuvant chemotherapy with or without trastuzumab...The pCR rate of PIK3CA-mutated patients (18.2%, 2/11) was significantly lower than that of PIK3CA wild-type patients (72.7%, 8/11), (P = 0.03)...Among patients treated with chemotherapy plus trastuzumab, all 8 patients with clonal PIK3CA-mutated did not achieve pCR.
Secondary therapy:
Chemotherapy
Trial ID:
